INTRODUCTION
Patients nearing death often experience distressing symptoms.
1 2 Many patients and physicians are confronted with complex decisions about practices surrounding end of life care that can affect the mode of dying. As an option of last resort, sedating drugs can be used. Such drugs induce a state of decreased consciousness and take away the patient's perception of symptoms. Sedation can be used intermittently or continuously until death, and the depth of the sedation can vary from a lowered state of consciousness to unconsciousness. All these varieties are covered by the term palliative sedation, but sedation to unconsciousness is also referred to as "terminal sedation." Physicians, medical organisations, scientists, ethicists, legal experts, and politicians are debating its use, with discussions focusing on the most extreme use of sedation-that is, continuous deep sedation until death. An important aspect of the debate concern the conditions under which this practice is medically indicated [3] [4] [5] [6] [7] [8] and the way it is performed. [8] [9] [10] [11] On the basis of their expertise and an extensive literature review, an expert group recently recommended that to warrant sedation at the end of life, the patient's condition should be irreversible and advanced, with death expected within at most one to two weeks. 8 Further recommendations were that benzodiazepines should be the drug of first choice, that hydration should be offered to sedated patients only when the benefit will outweigh the harm, and that advice from palliative care specialists should be sought before sedation.
Another important aspect of the debate is the question of when this practice is ethically acceptable. Is it slow euthanasia or is it a palliative intervention that should be clearly distinguished from euthanasia? [12] [13] [14] [15] [16] When the patient's life expectancy is short when sedation is started, continuous deep sedation presumably has no or only a limited effect on life shortening and is generally not considered to be the moral equivalent of euthanasia. When it is used for patients with a longer life expectancy with the intention to hasten the patient's death at his or her request, however, this practice should be regarded as the moral equivalent of euthanasia.
There is a lack of systematic large scale research on the use of continuous deep sedation because of the methodological, practical, and ethical difficulties related to the vulnerability of patients in their last phase of life. Most studies focus on particular settings and use different definitions. In 2001, a large scale study in six European countries showed that continuous deep sedation was used until death in 2.5-8.5% of all deaths, among patients with cancer and other diseases, and was provided in hospital as well as outside hospital. 17 For the Netherlands the estimated proportion was 5.6%. 17 Another study with a different design and a broader definition estimated that deep sedation until death was used in about 10% of all deaths in the Netherlands in 2001. 18 In 2005, as part of a larger study that evaluated the Dutch Euthanasia Act, we repeated the large scale nationwide study in the Netherlands. 19 The main findings of this study were that the enactment of the Dutch Euthanasia Act was followed by a modest decrease in the rates of euthanasia (from 2.6% of all deaths in 2001 to 1.7% of all deaths in 2005) and an increased application of continuous deep sedation until death (from 5.6% in 2001 to 7.1% in 2005). The increased use of a method that evokes such controversy, and at the same time represents an indispensable last resort option for unbearably suffering patients, indicates the need for more detailed insight. We compared consecutive data from 2005 with those from 2001 to provide an overview of recent developments in the use of continuous deep sedation in the Netherlands. We focused on the characteristics of the practice of continuous deep sedation until death and the patients who received such sedation.
METHODS

Study design and data collection
In 2005, we created a stratified sample of death certificates from the central death registry of Statistics Netherlands to which all deaths are reported. 19 We assigned all 43 959 deaths that occurred between August and November 2005 to one of five groups, according to the circumstances of death. In group 1 the cause of death precluded any physician assistance in dying (such as a car crash resulting in instant death), and we did not send out a questionnaire. Sampling fractions were larger for the groups in which it was more likely that a physician had assisted in the death. For all sampled cases in which we could not exclude the possibility of physician assistance, we sent the attending physicians a four page questionnaire. The final sample contained half the cases in group 5 (information on the death certificate made an end of life decision likely), 25% of the cases in group 4 (deaths from cancer and deaths that were probably preceded by long term terminal illness), 12.5% of those in group 3 (nonsudden death from chronic disease), 8 .3% of those in group 2 (sudden death with pre-existing disease), and all cases in group 1. The 2001 study was similar. 20 The design of both studies was largely the same, and further details have been described elsewhere. 19 20 Questionnaire For all sampled cases in which we could not preclude medical decision making before death, we asked the attending physician whether death had occurred suddenly and unexpectedly. If cases were reported as not sudden, we asked the attending physician to fill in a four page written questionnaire about the medical decision making that had preceded death. Of the 6860 questionnaires sent out, 5342 were completed and returned (78% response). The response percentage in 2001 was 74% (n=5189).
In 2005, the question that pertained to our definition of continuous deep sedation was: "Was the patient continuously and deeply sedated or kept in coma until death?" Follow-up questions were "Which medication was given for sedation?" (midazolam, other benzodiazepine, morphine or a morphine derivative, or other types of medication) and "How long before the patient's death was continuous sedation started?" We asked these questions for all non-sudden deaths. In 2001, physicians were asked "Did the patient receive drugs, such as barbiturates or benzodiazepines, to keep him/her continuously in deep sedation or coma until death?" In 2001, this was asked only for deaths where an end of life decision had (potentially) hastened death, such as intensified alleviation of symptoms with a potential effect on life shortening or the withholding of potentially life prolonging treatments.
The 2005 questionnaire contained additional questions referring to aspects of medical care and treatment before the patient's death and the presence of symptoms, despite possible treatment, during the last 24 hours of life. It also asked whether an expert in palliative care was consulted during the month before death. Physicians were asked to estimate the effect on life shortening, if any, of the decision making before death. We collected data regarding the patient's age, sex, and cause of death from the death certificate.
Analyses
The percentages reported are weighted to adjust for differences in the sampling fractions and for differences in response rates in relation to the patient's sex, age, marital status, region of residence, and place and cause of death. After adjustment, we extrapolated the percentages to cover a 12 month period to reflect the 136 402 deaths in the Netherlands in 2005. Weighting factors were calculated in three steps. Firstly, we took the inverse of the percentage of deaths sampled from each group and multiplied the resulting factor by a second factor that was calculated by dividing the sampled number of deaths by the number of deaths for which we received a questionnaire from the physician for each combination of characteristics of patients. The weighting factor that resulted from step 1 and 2 was multiplied by a factor that was calculated in the third step, by dividing the actual number of cases in the population of dead people in 2005 for each combination of characteristics of patients by the number of cases from the first two weighting steps. We calculated confidence intervals for the main findings. We compared the prevalence of symptoms in patients for whom continuous deep sedation had been started during the last 24 hours of life with the prevalence of symptoms in all patients in whom death was not sudden. We excluded missing values when these comprised less than 5% of all cases. Statistical analyses were performed with SPSS 11.0 (SPSS, Chicago, IL). For 47% of all patients who received continuous deep sedation, the sedation was started in the last 24 hours before death (see table 4 ). For these patients, 42-55% were reported as experiencing pain, fatigue, dyspnoea, and unclear consciousness in the last 24 hours of life and 23% and 21% had confusion and anxiety (table 3) . Most patients had more than one symptom, and 74% experienced symptoms that are common indications for sedation-that is, pain, dyspnoea, confusion, or anxiety. Sedated patients had more symptoms than other patients who did not die suddenly and more often experienced dyspnoea, pain, and anxiety. Table 4 examines the characteristics of the practice of continuous deep sedation in 2005. No comparable data were available from 2001. In 83%, continuous deep sedation was induced with benzodiazepines often combined with morphine. Such a combination was most often used by clinical specialists. Morphine was used without benzodiazepines in 15%. Nursing home physicians and general practitioners reported using benzodiazepines relatively often (89% and 87%, respectively), whereas clinical specialists were more likely to administer morphine for sedation (19% of cases). Palliative consultation in the month before death was quite rare (9%), and most often sought by general practitioners (20% of cases). Palliative consultation was positively related to the use of benzodiazepines (whether or not combined with other drugs) (P<0.01). For almost all of the patients for whom sedation was used, general practitioners and nursing home physicians withheld artificial nutrition and hydration, whereas this was true for 30% of the patients attended by clinical specialists. In two thirds, physicians estimated that the effect of the decision making before death on shortening life was 24 hours or less. In 6% of the cases, patients were sedated for more than one week (11% among clinical specialists). In 9% of the cases, the decision to use continuous deep sedation was preceded by an explicit request from the patient to end his or her life by means of euthanasia or assisted suicide, which was not granted. General practitioners reported this more often (16%) than clinical specialists (4%) and nursing home physicians (9%). The most frequently cited reason why the physician had not granted the patient's request was that the time frame to complete the euthanasia procedure was too short-for example, because of the obligation to consult another physician (40%, n=24). Other reasons mentioned were that the suffering of the patient was not considered to be unbearable (10%, n=4) and that the patient had withdrawn the request for euthanasia (9%, n=6).
RESULTS
DISCUSSION
In the Netherlands the increase in the use of continuous deep sedation for patients nearing death mostly occurred among general practitioners and clinical specialists, especially for patients with cancer. Patients for whom sedation was started in the last 24 hours of their life more often had dyspnoea, pain, and anxiety than other patients whose death was not sudden. In about four out of every five patients sedation was induced with benzodiazepines. Clinical specialists were more likely than general practitioners and nursing home physicians to use other drugs, mostly morphine. Physicians rarely sought palliative consultation, although this happened more often among general practitioners. In about one in every 10 patients, the use of continuous deep sedation was preceded by a request for euthanasia or assisted suicide that was not granted.
Strengths and weaknesses of the study
The large random samples of death certificates and high response rates in both years ensure generalisability to all deaths in the Netherlands. That the study design was similar in both years, authoritative medical bodies endorsed the study, and anonymity of patients and physicians was guaranteed further strengthen the validity and reliability of our results. In the 2005 questionnaire, there were small adjustments in the wording of the key questions regarding the use of continuous deep sedation. Because we did not change the key elements of our definition (continuous and deep sedation or coma until death) we believe this did not affect our results.
Strengths and weaknesses in relation to other studies
To minimise possible differences in the perception of sedation across the respondents we provided them with a descriptive definition of the practice (continuous deep sedation until death). Most other studies use terms such as palliative or terminal sedation, which can have varying connotations and implications for normal practice. In 2005 continuous deep sedation until death was used in 8.2% of all deaths. The proportion of continuous deep sedation was highest (10%) among patients attended by clinical specialists compared with the other specialties. This is in line with a study performed in six European countries in 2001, where the highest rates of continuous deep sedation were also found among patients who died in hospitals compared with elsewhere (2.9-13.2%), except for Italy, where sedation rates were higher outside the hospital. 17 Furthermore, our findings show an increase in the use of continuous deep sedation until death in the studied period, especially among general practitioners. This agrees with results of another Dutch longitudinal study. 21 While half of the sedated patients in our study had cancer, continuous deep sedation was also used for patients with cardiovascular diseases, pulmonary diseases, and diseases of the nervous system, similar to the 2001 European study. 17 Most other studies report the use of continuous deep sedation only for patients with cancer, probably because they were restricted to specific settings such as palliative care units. [22] [23] [24] [25] Furthermore, in the last 24 hours of life, many patients for whom sedation was started in this period experienced dyspnoea, pain, and fatigue. Anxiety and confusion were reported for one in five patients. Symptoms reported by other studies were not restricted to the last 24 hours and focused on indications rather than on symptoms. In those studies, delirium or terminal restlessness, dyspnoea, and pain *Score 4 or 5 on a scale of 1 (symptom not present) to 5 (symptom strongly present despite treatment). †Weighted for sampling fractions, non-response, and random sampling deviations ‡In patients in whom sedation was started in 0-24 hours before death (n=238). Symptoms missing for 6-16% of patients. §Excludes cases of continuous deep sedation (n=3334). Symptoms were missing for 7-14% of patients.
are frequently mentioned indications for sedation, 18 22-24 26 27 which seems to agree with our findings.
We found that 15% of patients were sedated with morphine as a single therapy. Two other nationwide Dutch studies conducted in 2001 and 2005 found somewhat higher levels of use (36% 18 and 28%, 10 respectively). Similar to our findings, both studies showed that clinical specialists were more likely than general practitioners and nursing home physicians to use morphine for this purpose. 10 18 Most patients (94%) were sedated for less than one week, which is also comparable with results of other studies.
22-24 28
Interpretation There could be several explanations for the increase in the use of continuous deep sedation until death seen between 2001 and 2005. Physicians and medical authorities have paid more attention to continuous deep sedation and knowledge has increased. From 2002 on, for example, regional cancer centres have published guidelines to improve its application, and in 2005 (after our data collection) a nationwide guideline was released in the Netherlands. 29 The practice of continuous deep sedation until death also recently received a lot of attention in the media. These developments could have led to an increased interest in its use among physicians as well as patients and their relatives.
Continuous deep sedation has possibly increasingly been used as a relevant alternative to euthanasia. The use of euthanasia had decreased from 2.6% of all deaths in 2001 to 1.7% of all deaths in 2005 (a decrease of 1200 cases), 19 while continuous deep sedation increased by 1800 cases from 5.6% to 7.1%. This increase took place mostly in the subgroups in which euthanasia is most common: patients attended by general practitioners and those with cancer. In 9% of the patients, the use of continuous deep sedation was preceded by a request for euthanasia that was not granted. Although euthanasia and continuous deep sedation generally address different clinical problems, 16 this suggests that substitution might be possible in some situations. This is in line with the finding that many Dutch physicians have been found to consider high quality end of life care as an alternative to euthanasia. 20 We do not know whether such substitution is always in accordance with the patient's wishes and with legal and professional guidelines. As long as the life expectancy of the patient is short at the time that sedation is started, continuous deep sedation presumably has no or only a limited effect on life shortening. In such cases, continuous deep sedation might be considered as normal medical practice, which does not require special judicial supervision such as with euthanasia. For patients with a longer life expectancy, there is a risk that labelling the decision as continuous deep sedation instead of ending of life might serve as a way to evade the procedural requirements for euthanasia. Our study shows, however, that the estimated effect on life shortening was, in most cases, limited. Future studies about medical practices at the end of life should evaluate this in more detail. Around 15% of the physicians used morphine without a benzodiazepine to attain sedation. Most guidelines at present recommend the use of benzodiazepines for deep sedation, while morphine is usually rejected as a single therapy to attain sedation because of its unpredictable sedative and side effects. A previous Dutch study suggested that the choice of drugs for continuous deep sedation is associated with the use of guidelines and being a palliative expert or consultation of a palliative care expert. 10 Our study confirmed the relation between consultation and adequate drug use. Such consultation, however, occurred in only a small number of the cases in our study, maybe because most of the physicians consider the application of continuous deep sedation as normal medical practice that is part of their own expertise or because they were not well informed about it or did not have access to palliative consultation. Increased use of palliative consultation might improve the clinical performance of continuous deep sedation.
Unanswered questions and future research Future research should focus on the underlying reasons for the use of continuous deep sedation. The perspectives of physicians as well as the wishes of patients and relatives should be taken into account. Specific attention should be directed at the substitution of euthanasia by continuous deep sedation, especially in general practice because euthanasia in the Netherlands usually takes place at home. Research should include a longitudinal timeframe to investigate how the practice of continuous deep sedation will further develop. This should be done nationally and internationally to allow comparisons and increase understanding of the reasons for the use of this practice. Lastly, rendering patients unconscious until death is a far reaching intervention that has an important impact on the dying process for both the patient and the relatives. Whether and how such sedation contributes to a dignified death deserves further study.
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WHAT IS ALREADY KNOWN ON THIS TOPIC
Continuous deep sedation until death is sometimes used in severely suffering patients with refractory symptoms; in the Netherlands use increased from 5.6% of all deaths in 2001 to 7.1% in 2005 Guidelines recommend the use of benzodiazepines for deep sedation, while morphine is usually rejected as a single therapy to attain sedation because of its unpredictable sedative and side effects Continuous deep sedation and euthanasia are generally used in different clinical situations
WHAT THIS STUDY ADDS
The increase in the use of continuous deep sedation until death in the Netherlands was mostly because of an increase in use by general practitioners, especially for patients with cancer
Of the physicians who used continuous deep sedation, 15% used morphine and no benzodiazepines and 91% did not consult a palliative care expert
The use of euthanasia decreased while the use of continuous deep sedation increased, especially in subgroups in which euthanasia is most common; and 9% of patients who received continuous deep sedation had previously asked for euthanasia but their requests were not granted
